Stock Information In this section you will find detailed information regarding the Evotec SE share, ranging from basic share data over stock charts, shareholder structure, our financial analysts, our auditors to our dividend policy. BASIC SHARE DATA Security identification numbers Listing on Frankfurt Stock Exchange (XETRA) Ordinary bearer shares ISIN: DE0005664809 Listing NASDAQ, New York American Depositary Shares (“ADSs”) ISIN: US30050E1055 Ticker symbol Listing on Frankfurt Stock Exchange (XETRA) Frankfurt Stock Exchange: EVT Listing NASDAQ, New York NASDAQ: EVO Bloomberg Xetra: EVT GY Equity Reuters Xetra: EVTG.DE Stock exchange Listing on Frankfurt Stock Exchange (XETRA) Frankfurt Stock Exchange Listing NASDAQ, New York NASDAQ New York Segment Listing on Frankfurt Stock Exchange (XETRA) Prime Standard Listing NASDAQ, New York Global Select Market Index Listing on Frankfurt Stock Exchange (XETRA) MDAX, TecDAX, Prime All Share, LTecDAX, Technology All Share, CDAX Listing NASDAQ, New York n/a Designated Sponsor Listing on Frankfurt Stock Exchange (XETRA) ODDO SEYDLER BANK AG Listing NASDAQ, New York Paying agent Listing on Frankfurt Stock Exchange (XETRA) Deutsche Bank AG, Frankfurt am Main Listing NASDAQ, New York J.P. Morgan Number of shares issued Listing on Frankfurt Stock Exchange (XETRA) 175,412,241 ordinary bearer shares Listing NASDAQ, New York 20,000,000 ADSs (10,000,000 ordinary shares) Nominal capital Listing on Frankfurt Stock Exchange (XETRA) € 175,412,241 Listing NASDAQ, New York € 175,412,241 SHARE PRICE SUMMARY 2020 Listing on Frankfurt Stock Exchange (XETRA) High (28 December): € 30.30 Listing on Frankfurt Stock Exchange (XETRA) Low (12 March): € 18.69 Listing on Frankfurt Stock Exchange (XETRA) Opening Price: € 23.79 Listing on Frankfurt Stock Exchange (XETRA) Closing Price: € 30.28 Listing on Frankfurt Stock Exchange (XETRA) Weighted average number of shares outstanding: 165,110,695 Listing on Frankfurt Stock Exchange (XETRA) Total number of shares outstanding as at 31 Dec: 165,110,695 Listing on Frankfurt Stock Exchange (XETRA) Average daily trading volume (all exchanges): 1,466,481 Listing on Frankfurt Stock Exchange (XETRA) Market capitalisation as at 31 Dec: € 4,963.34 m Listing on Frankfurt Stock Exchange (XETRA) Earnings per share (diluted/basic): € 0.04/€ 0.04 Listing on Frankfurt Stock Exchange (XETRA) Dividend per share: € 0.00 Expand table LISTING ON NASDAQ Since November 2021 Evotec SE is listed on NASDAQ (Ticker Symbol: EVO). Please find all further information regarding the NASDAQ listing as well as al published filings of Evotec SE under the following link: Link to SEC/EDGAR STOCK PRICE & CHART SHAREHOLDER STRUCTURE On 15 November 2021, the number of total voting rights amounts to 175,412,241. Under the German Securities Trading Act (Wertpapierhandelsgesetz, WpHG), shareholders of a listed German company are required to notify the Company and the German Federal Financial Supervisory Authority (BaFin) of any change to the voting interest in Evotec SE whenever it reaches, exceeds or falls below specified thresholds (3%, 5%, 10%, 15%, 20%, 25%, 30%, 50% or 75% of the voting rights). Evotec’s voting rights announcements can be found at dgap.de. Three shareholders, Novo Holdings A/S, T. Rowe Price Group Inc. and Mubadala Investment Company, currently hold more than 5% of the shares of Evotec SE. The free float according to the definition of the Frankfurt Stock Exchange is approx. 68% according to our estimates (Evotec: 11|2021). Shareholder structure (in %)* * Rounding differences may occur. ANALYSTS Overview of analysts covering the Evotec share Citigroup Inc. Peter Verdult Citigroup Inc. Peter Verdult One Court Square, 45th Floor, Long Island City, New York 11120, USA Contact peter.verdult@citi.com vCard LATEST ANALYST RECOMMENDATIONS Below you will find the latest analyst recommendations. Analyst Citigroup Inc. Recommendation BUY Target Price 29.50 EUR Date of the latest Research Report 1 September 2020 Analyst Deutsche Bank Recommendation HOLD Target Price 38.00 EUR Date of the latest Research Report 16 August 2021 Analyst Frankfurt Main Research (FMR) Recommendation BUY Target Price 36.50 EUR Date of the latest Research Report 3 February 2021 Analyst goetzpartners securities Limited Recommendation OUTPERFORM Target Price 40.00 EUR Date of the latest Research Report 20 May 2021 Analyst Intron Health Recommendation BUY Target Price 30.00 EUR Date of the latest Research Report 13 October 2020 Analyst Kempen & Co. N.V. Recommendation BUY Target Price 40.00 EUR Date of the latest Research Report 11 May 2021 Analyst Stifel Europe Bank Recommendation HOLD Target Price 38.50 EUR Date of the latest Research Report 15 July 2021 Analyst Royal Bank of Canada (RBC) Recommendation OUTPERFORM Target Price 39.00 EUR Date of the latest Research Report 11 May 2021 Analyst Rx Securities Recommendation BUY Target Price 50.00 EUR Date of the latest Research Report 26 October 2021 Analyst Warburg Research Recommendation BUY Target Price 48.00 EUR Date of the latest Research Report 27 October 2021 Analyst Average Target Price Recommendation Target Price 38.95 EUR Date of the latest Research Report CURRENT ANALYST CONSENSUS (HALF-YEAR 2021) DOWNLOADS Analyst consensus H1 2021 XLSX, 55.0 KB Important Notice: Evotec is covered and evaluated by the analysts mentioned above. Please note that any opinions, estimates or forecasts regarding Evotec's performance made by these analysts are theirs alone and do not represent opinions, estimates or forecasts of Evotec or its management. The above reference to the analysts does not imply that Evotec endorses their opinions. Evotec is under no obligation to update or supplement the information provided above and does not guarantee the accuracy or completeness of this list. Copies of the reports from the analysts listed above can be obtained directly from the analysts or their employers. Due to legal requirements Evotec is not allowed to publish the analyst reports. EVOTEC'S DIVIDEND POLICY The payment of dividends depends on Evotec’s financial situation and liquidity requirements, general market conditions, and statutory, tax and regulatory requirements. Evotec has never paid or declared any cash dividends on its ordinary shares, and does not anticipate paying any cash dividends on its ordinary shares in the foreseeable future. Evotec intends to retain all available funds and any future earnings and reinvest them in the company’s further growth strategy to better leverage longterm growth and sustainability. Under German law, Evotec may pay dividends only from the distributable profit (Bilanzgewinn) reflected in its unconsolidated financial statements (as opposed to the consolidated financial statements for Evotec and its subsidiaries) prepared in accordance with the principles set forth in the German Commercial Code (Handelsgesetzbuch) and adopted by the Evotec Management Board (Vorstand) and the Supervisory Board (Aufsichtsrat), or, as the case may be, by the shareholders of Evotec in a general shareholders’ meeting. In addition, under German law Evotec may not pay dividends before annual profits exceed the losses carried forward. All of the shares represented by the ADSs offered in USA generally have the same dividend rights as all of Evotec's other outstanding shares. TOP RSS Twitter LinkedIn EVOTEC @Evotec A new approach to off-the-shelf cancer vaccines - https://t.co/4Re4h5FDGx | Our latest blog details Dendritic Cells… https://t.co/xB7m0D5k8k 02:08 PM - 24 NOVEMBER 2021